Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2018 1
2019 1
2021 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Autoimmune Responses in Oncology: Causes and Significance.
Bareke H, Juanes-Velasco P, Landeira-Viñuela A, Hernandez AP, Cruz JJ, Bellido L, Fonseca E, Niebla-Cárdenas A, Montalvillo E, Góngora R, Fuentes M. Bareke H, et al. Among authors: bellido l. Int J Mol Sci. 2021 Jul 27;22(15):8030. doi: 10.3390/ijms22158030. Int J Mol Sci. 2021. PMID: 34360795 Free PMC article. Review.
Adjuvant dabrafenib and trametinib for patients with resected BRAF -mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
Manzano JL, Martin-Liberal J, Fernández-Morales LA, Benítez G, Medina Martínez J, Quindós M, García-Castaño A, Fernández O, Simo RV, Majem M, Bellido L, Ayala de Miguel P, Campos B, Espinosa E, Macías Cerrolaza JA, Gil-Arnaiz I, Lorente D, Rodriguez-Lescure A, Perez VN, López Castro R, Gramaje MG, Puértolas T, Rodriguez Moreno JF, Espasa Font L, Belaustegui Ferrández G, Cerezuela-Fuentes P. Manzano JL, et al. Among authors: bellido l. Melanoma Res. 2023 Oct 1;33(5):388-397. doi: 10.1097/CMR.0000000000000888. Epub 2023 Mar 28. Melanoma Res. 2023. PMID: 36988401 Free PMC article.
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Gonzalez-Cao M, Mayo de Las Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, Arance A, Muñoz-Couselo E, Espinosa E, Puertolas T, Diaz Beveridge R, Ochenduszko S, Villanueva MJ, Basterretxea L, Bellido L, Rodriguez D, Campos B, Montagut C, Drozdowskyj A, Molina MA, Lopez-Martin JA, Berrocal A. Gonzalez-Cao M, et al. Among authors: bellido l. Nat Commun. 2021 Dec 1;12(1):7008. doi: 10.1038/s41467-021-26572-6. Nat Commun. 2021. PMID: 34853302 Free PMC article. Clinical Trial.
Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays.
González-González M, Sayagués JM, Muñoz-Bellvís L, Pedreira CE, de Campos MLR, García J, Alcázar JA, Braz PF, Galves BL, González LM, Bengoechea O, Abad MDM, Cruz JJ, Bellido L, Fonseca E, Díez P, Juanes-Velasco P, Landeira-Viñuela A, Lecrevisse Q, Montalvillo E, Góngora R, Blanco O, Sánchez-Santos JM, LaBaer J, Orfao A, Fuentes M. González-González M, et al. Among authors: bellido l. Cancers (Basel). 2021 May 31;13(11):2718. doi: 10.3390/cancers13112718. Cancers (Basel). 2021. PMID: 34072782 Free PMC article.
Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).
Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A. Martin-Broto J, et al. Among authors: bellido l. Oncologist. 2019 Jun;24(6):e338-e346. doi: 10.1634/theoncologist.2018-0121. Epub 2018 Nov 8. Oncologist. 2019. PMID: 30409793 Free PMC article.
Case 3. Upper limb lymphangiosarcoma following breast cancer therapy.
Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ. Ocaña A, et al. Among authors: bellido l. J Clin Oncol. 2006 Mar 20;24(9):1477-8. doi: 10.1200/JCO.2005.01.8473. J Clin Oncol. 2006. PMID: 16549844 No abstract available.
Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients.
Ocaña A, Rodríguez-Barbero A, Pericacho M, Bellido L, Seijas R, López R, Delgado C, de Prado DS, Cruz-Hernández JJ, López-Novoa JM. Ocaña A, et al. Among authors: bellido l. Cancer Lett. 2007 Sep 18;255(1):71-6. doi: 10.1016/j.canlet.2007.03.020. Epub 2007 May 4. Cancer Lett. 2007. PMID: 17482348